Post by LabRulezLCMS (EN)

A new route against MDR Acinetobacter baumannii! 🧫🛡️ Trisubstituted pyridines that inhibit ATP synthase show promise as next‑gen antibiotics in ACS Omega 2025. • Why it matters: MDR A. baumannii resists “last‑line” drugs and threatens hospitals worldwide ⚠️ • What’s new: 34 pyridines synthesized; four leads （WSA 276, WSA 288, WSA 289, WSA 298） delivered potent, selective activity against susceptible and MDR isolates 💥 • How it works: They target bacterial bioenergetics—ATP synthase—binding at the Fo c‑subunit （salt bridge to cAsp60） 🧬🔬 • Synergy: Strong combo effects with colistin ➕🤝 • Caveat: Some cytotoxicity observed; optimization underway to boost selectivity and safety ⚗️🧪 • By: Angelina L. Dennison, Armaan Singh, Toni Marchlewski, Sierra Ghee, Kevin Gencel , Ava G. Hammock, Sabrina Liu, Shaylla Wilson, Alexander P. L. Williams, Katie Ward, Thomas E. (Ted) Meigs, Ryan Steed*, and Amanda Wolfe* • Read more: ACS Omega 📖 #AntimicrobialResistance #Acinetobacter #ATPsynthase #DrugDiscovery #MedicinalChemistry #Antibiotics #Synergy #Colistin #ACS #MDR